STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRZM
  4. [8-K] MARIZYME, INC. Reports Material Event

Marizyme (MRZM) shifts assets into assignment for benefit of creditors

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Marizyme, Inc. approved and executed a general assignment for the benefit of creditors, transferring all or substantially all of its assets to an assignee. On April 9, 2026, the Board determined this assignment was in the company’s best interests and authorized an Assignment Agreement with Peter Hurwitz as assignee, which was signed on April 14, 2026. The company states this transaction constitutes an assignment for the benefit of creditors proceeding under Chapter 727, Florida Statutes, and it is reported under the Bankruptcy or Receivership and Disposition of Assets items.

Positive

  • None.

Negative

  • Board-approved assignment for the benefit of creditors transfers all or substantially all company assets to an assignee, indicating severe financial distress and entry into an insolvency-type proceeding.
  • Bankruptcy or Receivership disclosure under Item 1.03, tied to a Chapter 727, Florida Statutes process, signals that creditor interests now dominate and equity recovery is likely at significant risk.

Insights

Marizyme has entered a state-law insolvency process, signaling severe financial distress.

Marizyme’s Board approved a general assignment for the benefit of creditors, transferring all or substantially all assets to an assignee. This is a formal liquidation mechanism similar in effect to bankruptcy, aimed at distributing asset value to creditors.

The move is reported under Bankruptcy or Receivership and Disposition of Assets, underscoring that this is not a routine transaction. An assignee plans to commence proceedings in the Fifteenth Judicial Circuit in Palm Beach County, Florida under Chapter 727, concentrating control of remaining value with the insolvency estate.

For stakeholders, this typically means creditor recovery takes priority, and equity often holds residual or no value, depending on asset realizations and claim hierarchy as the Chapter 727 process advances in Florida state court.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 1.03 Bankruptcy or Receivership Business
The company or a significant subsidiary has filed for bankruptcy or entered receivership.
Item 2.01 Completion of Acquisition or Disposition of Assets Financial
The company completed a significant acquisition or sale of business assets.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Board determination date April 9, 2026 Date Board found assignment for benefit of creditors in company’s best interests
Assignment Agreement date April 14, 2026 Date Marizyme executed Assignment Agreement with assignee Peter Hurwitz
Planned petition deadline On or before April 17, 2026 Target for assignee to file Chapter 727 petition in Florida court
assignment for the benefit of creditors financial
"authorized the Company to enter into a general assignment for the benefit of creditors"
Material Definitive Agreement regulatory
"Item 1.01. Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Bankruptcy or Receivership regulatory
"Item 1.03. Bankruptcy or Receivership."
Chapter 727, Florida Statutes regulatory
"in accordance with Chapter 727, Florida Statutes on or before April 17, 2026."
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did Marizyme (MRZM) announce in this 8-K filing?
Marizyme disclosed that its Board approved and executed a general assignment for the benefit of creditors, transferring all or substantially all assets to an assignee. This represents a formal insolvency-type process under Chapter 727, Florida Statutes, rather than a routine business transaction.

What is an assignment for the benefit of creditors in Marizyme’s case?
For Marizyme, the assignment for the benefit of creditors involves transferring all or substantially all assets to an assignee, Peter Hurwitz. The assignee will oversee a court-supervised process in Florida to address creditor claims under Chapter 727, effectively placing remaining asset value into an insolvency estate.

When did Marizyme’s Board approve and sign the Assignment Agreement?
Marizyme’s Board determined on April 9, 2026 that entering a general assignment for the benefit of creditors was in the company’s best interests. The company then executed the Assignment Agreement with assignee Peter Hurwitz on April 14, 2026, formally transferring control of substantially all assets.

How does this filing indicate bankruptcy or receivership for Marizyme (MRZM)?
Marizyme reports the transaction under the Bankruptcy or Receivership item, incorporating details of the Assignment Agreement. The assignee intends to commence proceedings in the Fifteenth Judicial Circuit in Palm Beach County, Florida under Chapter 727, confirming that the company has entered a formal insolvency framework.
false 0001413754 0001413754 2026-04-14 2026-04-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 14, 2026

 

Marizyme, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   000-53223   82-5464863

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

1645 Palm Beach Lakes Drive, Suite 1200

West Palm Beach, Florida 33401

(Address of principal executive offices, including zip code)

 

(561) 935-9955

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:   Trading Symbol   Name of Each Exchange on which Registered
Not applicable.        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On April 9, 2026, the Board of Directors (the “Board”) of Marizyme, Inc. (the “Company”) (i) determined that the transfer of all or substantially all of the Company’s assets through an assignment for the benefit of creditors was in the best interests of the Company, and (ii) authorized the Company to enter into a general assignment for the benefit of creditors (the “Assignment Agreement”), by and between the Company and Peter Hurwitz, as assignee (the “Assignee”), which provides for the transfer of all or substantially all of the Company’s assets to the Assignee (the “Assignment”). The Company entered into the Assignment Agreement on April 14, 2026.

 

The foregoing descriptions of the Assignment Agreement and the Assignment are only a summary and are qualified in their entirety by reference to the complete text of the Assignment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Item 1.03. Bankruptcy or Receivership.

 

The information contained above in Item 1.01 relating to the Assignment Agreement and the Assignment is hereby incorporated by reference into this Item 1.03.

 

The Assignee intends to commence an assignment for the benefit of creditors proceeding by filing a petition in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida in accordance with Chapter 727, Florida Statutes on or before April 17, 2026.

 

Item 2.01. Completion of Acquisition or Disposition of Assets.

 

The information contained above in Item 1.01 relating to the Assignment Agreement and the Assignment is hereby incorporated by reference into this Item 2.01.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
     
10.1*   Assignment for the Benefit of Creditors, dated April 14, 2026, by and between Marizyme, Inc. and Peter Hurwitz
     
104   Cover Page Interactive Data File

 

 

* Schedules (or similar attachments) have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished to the SEC upon request.

 

 
 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MARIZYME, INC.
     
Dated: April 17, 2026 By: /s/ David Barthel
  Name: David Barthel
  Title: Chief Executive Officer

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents